

IFW

Docket No. CEN 5008 CIP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on

JUNE 17, 2004 (Date of Deposit)

KIRK BAUMEISTER

(Name of applicant, assignee, or Registered Representative)

JUNE 17, 2004

(Date of Signature)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LEE ET AL

Serial No. : 10/727,432

Art Unit:

Filed

: DECEMBER 4, 2003

Examiner:

For

: CLONAL MYELOMA CELL LINES USEFUL FOR MANUFACTURING

PROTEINS IN CHEMICALLY DEFINED MEDIA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with  $\square$  the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/CEN5008CIP/KB the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

	Statement in Accordance with §1.97(e) (attached); or
_	
L	Please charge Deposit Account No. 10-
	0750/CEN5008CIP/KB the fee of \$180.00 as set
	forth in §1.17(p).
I:	n accordance with §1.97(d), this Information
Disclosure :	Statement is being filed after the mailing date of
either a Fir	nal Action under §1.113 or a Notice of Allowance
under §1.3	ll but before the payment of the Issue Fee.
Applicant(s	hereby petition(s) for consideration of this
Information	Disclosure Statement. Included are: Statement in
Accordance v	with §1.97(e) as set forth below and the fee of
\$180.00 as	set forth in §1.17(p).
c	opies of each of the references listed on the
attached For	rm PTO-1449 are enclosed herewith.
57 0	onice of metawayan linked on the attached Dawn DEC
	opies of references listed on the attached Form PTO
1449 are en	closed herewith EXCEPT THAT:
Е	] In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
T	here are no listed references which are not in the
English lang	guage.

The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPFD 609 D

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5008CIP/KB. This form is submitted in triplicate.

Respectfully submitted,

KIRK BAUMEISTER Reg. No. 33,833

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: JUNE 17, 2004



-222PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

plays a valid Olvid Control number.		
10/727,432		
December 4, 2003		
Chi Chang Lee		
CEN 5008 CIP		

		U.S. Patent Do	cument			
Examiner Initials	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6274335	B1	Goeddel et al	08-14-2001	
		5723441		Higley et al	03-03-1998	
		6008195		Selsted	12-28-1999	
		4780313		Koichiro et al	10-25-1988	
		4504469		Melin et al	03-12-1985	
		5199942		Gillis	04-06-1993	

## FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Foreign Patent Document Date of Publication of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear Initials Office<sup>3</sup> Number⁴ KindCode<sup>5</sup> No.1

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450...

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are required to response

(use as many sheets as necessary)
Sheet 2 of 2

ond to a confection of information unless it disp	nays a valid Owib Control Humber.
Application Number	10/727,432
Filing Date	December 4, 2003
First Named Inventor	Chi Chang Lee
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5008 CIP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),  publisher, city and/or country where published	T
		HILL, M., ""Adaptive state of mammalian cells and its nonseparability suggestive of a quantum system," SCRIPTA MEDICA., 2000, PAGES 211-222, Vol. 73, No. 4.	
		FAULDS ET AL, "Abciximab: a review of its pharmacology and therapeutic potential in ischaemic heart disease," DRUGS, 1994, pages 583-598, Vol. 48, No. 4.	
		MOUSER ET AL, "Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease," CLINICAL THERAPEUTICS, 1999, pages 932-942, Vol. 21, No. 6, USA.	
		GORFIEN ET AL, "Growth of NSO cells in protein-free, chemically defined medium," LIFE TECHNOL INC., 2000, pages 682-687, Vol. 16, No. 5, USA.	
		LOUIS ET AL, "Maintenance of clonotypic myeloma cells in serum-free media," BLOOD, 2000, Abstract #4940, Vol. 96, No. 11, USA	
		FRESHNEY, R. IAN, "Culture of Animal Cells," A MANUAL OF BASIC TECHNIQUE, CHAPTER 7, pp. 92-3, UNIVERSITY OF GLASGOW.	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.